CRISPR-Directed Gene Editing as a Method to Reduce Chemoresistance in Lung Cancer Cells

Area of Science:

• Oncology
• Molecular Biology
• Gene Editing

Background:

• Cancer therapies (chemotherapy, radiation, immunotherapy) often face challenges due to acquired tumor resistance.
• Developing strategies to overcome or prevent this resistance is crucial for improving patient outcomes.
• CRISPR/Cas technology offers a precise tool for genetic manipulation.

Purpose of the Study:

• To present a novel CRISPR-directed gene editing strategy for treating solid tumors.
• To reduce the standard of care needed to halt or reverse tumor progression.
• To overcome acquired resistance to chemotherapy, radiation, and immunotherapy.

Main Methods:

• Utilizing CRISPR/Cas as a biomolecular tool to disable genes sustaining cancer therapy resistance.
• Developing a CRISPR/Cas molecule with tumor cell-specific genomic targeting capabilities.
• Employing a combinatorial approach with existing cancer therapies.

Main Results:

• Demonstrated methodology for using CRISPR/Cas to enhance chemotherapy efficacy against lung cancer cells.
• Experimental details provided for the application of this gene editing strategy.
• The approach aims to selectively target tumor cells, minimizing off-target effects.

Conclusions:

• CRISPR-directed gene editing represents a promising strategy to enhance current cancer treatments.
• This approach can potentially overcome acquired resistance, improving therapeutic effectiveness.
• Targeted delivery via direct injection is envisioned for solid tumors including lung, esophageal, and head and neck cancers.